Prostate Cancer Epidemiology In A Central Asian Region After Discontinuation Of Screening: Population-Based Data From Abay, Kazakhstan (2020-2024).

Q2 Medicine
Laura Zeinelova, Bayan Atantayeva, Bakytbek Apsalikov, Tolegen Kurmangaliyev, Mergyl Karipova, Erkezhan Ashimova, Sayat Tanatarov
{"title":"Prostate Cancer Epidemiology In A Central Asian Region After Discontinuation Of Screening: Population-Based Data From Abay, Kazakhstan (2020-2024).","authors":"Laura Zeinelova, Bayan Atantayeva, Bakytbek Apsalikov, Tolegen Kurmangaliyev, Mergyl Karipova, Erkezhan Ashimova, Sayat Tanatarov","doi":"10.31557/APJCP.2026.27.9.3393","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is one of the most common malignancies among men worldwide, with marked regional variability in incidence, mortality, and stage at diagnosis. Data from Central Asia remain limited, particularly in regions without organized prostate-specific antigen (PSA) screening programs. This study aimed to assess the epidemiology of prostate cancer in the Abay region of Kazakhstan during the post-screening period.</p><p><strong>Methods: </strong>A retrospective population-based descriptive study was conducted using official cancer registry data from the Abay region. All newly diagnosed prostate cancer cases (ICD-10 code C61) registered between 2020 and 2024 were included. Incidence, mortality, stage distribution at diagnosis, one-year lethality, prevalence, and the proportion of patients under ≥5-year follow-up in the cancer registry were analyzed using descriptive epidemiological methods. Year-to-year relative changes were used to describe temporal patterns in incidence and mortality.</p><p><strong>Results: </strong>A total of 260 new prostate cancer cases were registered during the study period. The incidence rate increased from 7.2 per 100,000 male population in 2020 to 9.2 per 100,000 in 2024, with a peak observed in 2023. In contrast, mortality declined steadily overall from 5.7 to 2.8 per 100,000 over the same period. Stage II disease predominated; however, advanced-stage cancer remained common. The proportion of stage IV disease ranged from 25.8% to 37.5%, indicating persistent late diagnosis. The proportion of patients registered in the cancer registry for ≥5 years increased from 42.1% to 56.4%, and prevalence rose from 55.4 to 63.6 per 100,000, reflecting the accumulation of patients under long-term observation.</p><p><strong>Conclusions: </strong>Despite increasing incidence, prostate cancer mortality in the Abay region declined during 2020-2024. However, the persistently high proportion of advanced-stage disease indicates substantial challenges in early detection in the absence of organized screening. These findings describe the current epidemiological profile of prostate cancer in a Central Asian region operating under opportunistic diagnostic practices.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3393-3398"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.9.3393","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prostate cancer is one of the most common malignancies among men worldwide, with marked regional variability in incidence, mortality, and stage at diagnosis. Data from Central Asia remain limited, particularly in regions without organized prostate-specific antigen (PSA) screening programs. This study aimed to assess the epidemiology of prostate cancer in the Abay region of Kazakhstan during the post-screening period.

Methods: A retrospective population-based descriptive study was conducted using official cancer registry data from the Abay region. All newly diagnosed prostate cancer cases (ICD-10 code C61) registered between 2020 and 2024 were included. Incidence, mortality, stage distribution at diagnosis, one-year lethality, prevalence, and the proportion of patients under ≥5-year follow-up in the cancer registry were analyzed using descriptive epidemiological methods. Year-to-year relative changes were used to describe temporal patterns in incidence and mortality.

Results: A total of 260 new prostate cancer cases were registered during the study period. The incidence rate increased from 7.2 per 100,000 male population in 2020 to 9.2 per 100,000 in 2024, with a peak observed in 2023. In contrast, mortality declined steadily overall from 5.7 to 2.8 per 100,000 over the same period. Stage II disease predominated; however, advanced-stage cancer remained common. The proportion of stage IV disease ranged from 25.8% to 37.5%, indicating persistent late diagnosis. The proportion of patients registered in the cancer registry for ≥5 years increased from 42.1% to 56.4%, and prevalence rose from 55.4 to 63.6 per 100,000, reflecting the accumulation of patients under long-term observation.

Conclusions: Despite increasing incidence, prostate cancer mortality in the Abay region declined during 2020-2024. However, the persistently high proportion of advanced-stage disease indicates substantial challenges in early detection in the absence of organized screening. These findings describe the current epidemiological profile of prostate cancer in a Central Asian region operating under opportunistic diagnostic practices.

停止筛查后中亚地区前列腺癌流行病学:来自哈萨克斯坦Abay的基于人群的数据(2020-2024)。
背景:前列腺癌是世界范围内男性最常见的恶性肿瘤之一,在发病率、死亡率和诊断阶段具有显著的地区差异。来自中亚的数据仍然有限,特别是在没有组织前列腺特异性抗原(PSA)筛查计划的地区。本研究旨在评估筛查后哈萨克斯坦阿贝地区前列腺癌的流行病学。方法:采用Abay地区官方癌症登记数据,进行了一项基于人群的回顾性描述性研究。2020年至2024年期间登记的所有新诊断的前列腺癌病例(ICD-10代码C61)都包括在内。采用描述性流行病学方法分析发病率、死亡率、诊断时分期分布、1年致死率、患病率和癌症登记中随访≥5年的患者比例。每年的相对变化被用来描述发病率和死亡率的时间模式。结果:研究期间共登记了260例前列腺癌新病例。发病率从2020年的7.2 / 10万男性人口增加到2024年的9.2 / 10万,并在2023年达到峰值。相比之下,同期死亡率总体稳步下降,从每10万人5.7人降至2.8人。II期为主;然而,晚期癌症仍然很常见。IV期疾病比例为25.8% ~ 37.5%,提示持续晚期诊断。癌症登记≥5年的患者比例从42.1%上升到56.4%,患病率从55.4 / 10万上升到63.6 / 10万,反映了长期观察患者的积累。结论:尽管发病率增加,但Abay地区的前列腺癌死亡率在2020-2024年期间下降。然而,持续高比例的晚期疾病表明,在缺乏有组织的筛查的情况下,早期发现存在重大挑战。这些发现描述了目前中亚地区在机会性诊断实践下前列腺癌的流行病学概况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
779
审稿时长
3 months
期刊介绍: Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书